Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,931,139

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Best Growth Stocks to Buy for February 27th

POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.

Ethan Feller headshot

Momentum Monday: Bull Market Continues

Want to start the week ahead of the pack? Check out Momentum Mondays

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Bruker's (BRKR) New Launches Drive Growth Amid FX Woes

Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.

Philips' (PHG) New Innovation to Boost Radiation-Free Imaging

Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Charles River (CRL) Forges Collaboration With Wheeler Bio

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up

Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Best Growth Stocks to Buy for February 23rd

CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.

Best Value Stocks to Buy for February 23rd

BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Best Income Stocks to Buy for February 23rd

AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.

New Strong Buy Stocks for February 23rd

IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.